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The Development of a Viral Mediated
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Expression for Inducible In vitro and
In vivo Genome Editing
Christopher A. de Solis, Anthony Ho, Roopashri Holehonnur and Jonathan E. Ploski *
School of Behavioral and Brain Sciences, Department of Molecular and Cell Biology, University of Texas at Dallas,
Richardson, TX, USA
The RNA-guided Cas9 nuclease, from the type II prokaryotic Clustered Regularly
Interspersed Short Palindromic Repeats (CRISPR) adaptive immune system, has been
adapted and utilized by scientists to edit the genomes of eukaryotic cells. Here, we report
the development of a viral mediated CRISPR/Cas9 system that can be rendered inducible
utilizing doxycycline (Dox) and can be delivered to cells in vitro and in vivo utilizing
adeno-associated virus (AAV). Specifically, we developed an inducible gRNA (gRNAi) AAV
vector that is designed to express the gRNA from a H1/TO promoter. This AAV vector is
also designed to express the Tet repressor (TetR) to regulate the expression of the gRNAi
in a Dox dependent manner. We show that H1/TO promoters of varying length and a
U6/TO promoter can edit DNA with similar efficiency in vitro, in a Dox dependent manner.
We also demonstrate that our inducible gRNAi vector can be used to edit the genomes
of neurons in vivo within the mouse brain in a Dox dependent manner. Genome editing
can be induced in vivo with this system by supplying animals Dox containing food for as
little as 1 day. This system might be cross compatible with many existing S. pyogenes
Cas9 systems (i.e., Cas9 mouse, CRISPRi, etc.), and therefore it likely can be used to
render these systems inducible as well.
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INTRODUCTION
The CRISPR/Cas9 based genome editing system has proven to be an extremely powerful tool for
scientists seeking to genetically manipulate cells and tissues in vitro and in vivo across multiple
species. This genome editing system takes advantage of the RNA-guided Cas9 nuclease from the
type II prokaryotic Clustered Regularly Interspersed Short Palindromic Repeats (CRISPR) adaptive
immune system, where it has been adapted for the use of knocking out genes, creating specific
modifications to genes and for the activation and suppression of transcription in a gene specific
manner (Jinek et al., 2012; Cong et al., 2013; Gilbert et al., 2013; Larson et al., 2013; Mali et al.,
2013; Qi et al., 2013; Sander and Joung, 2014; Tanenbaum et al., 2014). CRISPR/Cas9 can be used
to genetically manipulate embryonic stem cells quickly and relatively easily, which has enabled
genetically modified mice to be created significantly faster than conventional methodologies and
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this is especially true in cases where multiple genes are modified
(Wang et al., 2013). This system also offers a potentially better
alternative to RNAi mediated gene knockdown which requires
the constant overexpression of an shRNA to mediate gene
knockdown and in some cases has proven to be toxic when
utilized in vivo (Grimm et al., 2006; McBride et al., 2008; de Solis
et al., 2015).
The success of the CRISPR/Cas9 system can be explained, in
part, by its simplicity. For example, this genome editing system
can be reconstituted in eukaryotic cells simply by the presence
of the Cas9 protein and guide RNA (gRNA) consisting of the
fusion of a CRISPR RNA (crRNAs) and a fixed transactivating
CRISPR RNA (tracrRNA)—just two genes are required. The
first 20 nucleotides of the gRNA are custom designed to be
complementary to the intended target site within the genome
and consequently guide the Cas9 protein to this site, allowing
Cas9 to create double strand breaks (DSB) of the targeted DNA.
The DSB initiates the error prone nonhomologous end joining
(NHEJ) DNA repair mechanism. Due to the error prone nature
of this repair pathway, insertions and deletions (Indels) can be
created at the DSB break/repair site. If the DSB occurs within
the protein coding region of a gene, a loss of protein function
can occur due to: the deletion of relevant codons, an insertion
of inappropriate codons, or the creation of indels that lead
to a shift in the reading frame—collectively, leading to a null
allele/gene knockout. Alternatively, if a donor DNA template is
provided, Homology Directed Repair (HDR) can occur instead
of NHEJ. This phenomenon can be harnessed to create precise
modifications of the genome at specific loci (Cong et al., 2013;
Mali et al., 2013; Wang et al., 2013).
Recently, the CRISPR/Cas9 system has been rendered
amenable for delivery to cells in vivo via adeno-associated
virus (AAV) (Ran et al., 2015; Swiech et al., 2015). Delivery of
CRISPR/Cas9 via AAV could be useful for potential human gene
therapy approaches that might intend to utilize CRISPR/Cas9
technology and it is also highly relevant for preclinical studies
that could benefit from the delivery of CRISPR/Cas9 to tissues
of living mammals. The field of behavioral neuroscience can
greatly benefit from viral mediated genome editing because it can
be used to knock out genes in discrete locations of the animal
brain in a cell type specific manner to allow the interrogation of
how a gene influences behavior and circuit function. However,
in complex behavioral experiments it can be advantageous to
induce the desired genetic manipulation at a specific time point
during an ongoing experiment, but we are limited in our ability
to temporally control when genome editing will occur utilizing
existing technology.
Utilizing CRISPR/Cas9 systems in vivo, in mammals, may
allow these systems to be active for days to weeks at a time.
In cases where CRISPR/Cas9 might be virally delivered to
humans for gene therapy, the CRISPR/Cas9 system could be
active indefinitely. In these instances, where CRISPR/Cas9 is
chronically active for extended durations, there might be an
increase in the accumulation of off-target editing/mutations.
Thus, for in vivo applications, it would likely be beneficial to
minimize the duration of Cas9 mediated genome editing to the
time necessary for Cas9 to edit its intended target site and this has
been, in part, the motivation for developing previously described
inducible CRISPR/Cas9 genome editing systems (Davis et al.,
2015; Nihongaki et al., 2015; Zetsche et al., 2015). However,
while some of CRISPR/Cas9 systems have been adapted for AAV
delivery (Ran et al., 2015; Swiech et al., 2015; Karnan et al., 2016;
Yang et al., 2016), none of these AAV based systems, to date,
have been adapted to allow the genome editing function to be
temporally regulated.
Due to the benefits of possessing temporal control over the
duration of Cas9 mediated genome editing, we sought to develop
an inducible CRISPR/Cas9 system that could be virally delivered
and regulated utilizing Doxycycline (Dox). In our first set of
experiments, we attempted to regulate Cas9 expression from a
tetracycline response element containing promoter; however, we
determined that genome editing could not be regulated in a Dox
dependentmanner, due to the leakiness of Cas9 expressionwithin
this system. As an alternative, we developed a viral vector that
could regulate gRNA expression in a Dox dependent manner, and
we demonstrate that our two vector CRISPR/Cas9 system can be
virally delivered in vivo to the mouse brain and genome editing
can be induced in a Dox dependent manner. The inducible
gRNA vector (gRNAi) we developed is cross compatible with
many existing S. pyogenes Cas9 (SpCas9) systems and therefore
coupling our gRNAi AAV vector with these systems may enable
them to be inducible as well (i.e., Cas9 mouse, CRISPRi, etc.).
MATERIALS AND METHODS
Plasmid Construction
All viral plasmids generated for this study were produced
utilizing standard recombinant DNA cloning techniques. The
pAAV-pMecp2-SpCas9-spA plasmid (pX551) was a gift from
Feng Zhang’s laboratory (Swiech et al., 2015; Addgene #60957)
and this vector served as the backbone for the inducible Cas9
vectors described in this study. The truncated PTight sequence
was PCR amplified from pTRE-TIGHT-Cx43-eYFP [a gift from
Robin Shaw (Smyth et al., 2010; Addgene plasmid # 31807)] and
cloned into the AgeI-XbaI sites of pX551 to create the PTight-Cas9
vector. This truncated PTight sequence contained 3 Tet operators.
This vector was subsequently modified by cloning into the
BsmI-EcoR1 sites a new C-terminus region of Cas9 that lacked
the C-term NLS and instead contained the following core PEST
degron sequence (HGFPPAVAAQDDGTLPMSCAQESGMDRH;
Li et al., 1998) utilizing an appropriately designed gBlock
(Integrated DNA technologies) to create the PTight-Cas9PEST
vector. This core PEST sequence is utilized in the destabilized
eGFP variant, D1eGFP. To create the PTRE3G-Cas9PEST vector,
the truncated PTRE3G sequence was PCR amplified from pLenti
CMVTRE3G eGFP Neo (w821-1; A gift from Eric Campeau)
and cloned into the AgeI-KpnI sites of the PTight-Cas9PEST
vector. The truncated TRE3G promoter contains 2 Tet operators.
The PTRE3G-Cas9PEST vector was subsequently modified by
cloning in a new 5′ UTR/N-terminus region into the AgeI-BstXI
sites, utilizing an appropriately designed gBlock (Integrated
DNA Technologies), that lacked a Kozak sequence and the
N-Terminal NLS to create the PTRE3G-1Cas9-PEST viral vector.
To create the gRNA/rtTA-GFP viral vector, the previously
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described AAV2 genome vector, pAAV-shRNA expression
cassette vector, (Hommel et al., 2003) was systematically gutted
and the appropriate sequences were subsequently cloned into
it. First, the CMV-rtTA-GFP-Blastocidin S Resistance-WPRE
expression cassette was removed from pMA2640 (Addgene,
#25434; Alexeyev et al., 2010), and cloned into the XhoI-ClaI
sites of the pAAV-shRNA vector. A short ∼70 base pair 3′UTR
sequence containing two polyadenylation signal sequences,
which we’ve used previously (Holehonnur et al., 2015), was
cloned into the ClaI-MluI sites. The Blastocidin S Resistance
coding region was removed and the appropriate portion of
GFP with a stop codon was cloned back into the BamHI-MroI
sites. The gRNA expression cassette was PCR amplified from
pX330 [Gift from Feng Zhang (Cong et al., 2013; Addgene,
#42230)] using the following DNA primers, (gRNA RsrII
FP ataCGGTCCGgagggcctatttcccatgattccttc, gRNA XhoI RP
aacCTCGAGgccatttgtctgcagaattggcgcacg), and cloned into the
RsrII-XhoI sites, to create the final AAV2-gRNA/rtTA-GFP
viral vector. Because the BbsI sites used for cloning the gRNAs
into the gRNA expression cassette were not unique to this
AAV plasmid, the gRNAs were first cloned into the BbsI sites
of the pX330 plasmid and then the entire gRNA expression
cassette was transferred into the AAV plasmid via the RsrII-
XhoI sites utilizing the above mentioned DNA primers. The
DNA oligonucleotides coding for the Tet2 gRNAs compatible
with the pX330 plasmid were previously described (Wang
et al., 2013; Top: CACCGAAAGTGCCAACAGATATCC,
Bot: AAACGGATATCTGTTGGCACTTTC). The AAV2-
gRNAi-TetR viral vector was developed starting with the
AAV:ITR-U6-sgRNA(backbone)-hSyn-Cre-2A-EGFP-KASH-
WPRE-shortPA-ITR plasmid (Addgene, #60231; Platt et al.,
2014) as a backbone. The CMV promoter driving the TetR
coding region was PCR amplified from pQCXIN-TetR-mCherry
plasmid [a gift from Tom Misteli (Roukos et al., 2013; Addgene,
# 59417)] and it was inserted into this vector via the XbaI-NheI
sites. This resulted in the removal of the hSyn-Cre region.
Next, an inducible gRNA expression cassette containing an
HI/TO promoter was created using an appropriately designed
gBlock (Integrated DNA Technologies) and it was cloned
into the MluI-Xbal sites, to create the AAV2-gRNAi-TetR
viral vector. Guide RNA sequences can be cloned into this
vector via the SapI sites, in a similar manner as to how gRNA
sequences are cloned into the AAV:ITR-U6-sgRNA(backbone)-
hSyn-Cre-2A-EGFP-KASH-WPRE-shortPA-ITR plasmid
(Addgene, #60231; Platt et al., 2014) or the similar
pX552, pAAV-U6sgRNA-hSyn-GFP-KASH-bGH vector
(Addgene, # 60958). The Tet2 gRNA sequences used with
this vector were (Top: ACCGAAAGTGCCAACAGATATCC,
Bot: AACGGATATCTGTTGGCACTTTC). The entire
HI/TO gRNAi expression cassette can be PCR amplified
with the following DNA primers [H1TO gRNA FP (MluI)
AGCTACGCGTAATATTTGCATGTC and H1TO gRNA RP
(XbaI) ACGTTCTAGAACTAGTCCATGG]. The entire U6/TO
and H1-L/TO expression cassettes containing the Tet2 gRNA
were PCR amplified from appropriately designed gBlocks
(Integrated DNA Technologies) and inserted into the AAV2-
gRNAi-TetR viral vector via the MluI-XbaI sites. The DNA
sequences for these new plasmids will be made available upon
request. All gRNA viral plasmids will be made available through
Addgene.
Assessment of In vitro Genome Editing
For in vitro genome editing experiments, Neuro-2a cells (N2A;
ATCC) were grown to a confluency of 60–65% in a 24 well
cell culture plate and transfected with a plasmid containing a
Cas9 transgene and a plasmid containing a gRNA transgene
in a 1:1 ratio with Lipofectamine 2000 (Invitrogen), following
the manufacturer’s instructions. In cases where pX330Tet2 or
pX330Empty were used, only one plasmid was transfected.
For samples that required Doxycycline (Dox), the media was
replaced with fresh media 6 h post transfection that contained
10 µg/mL of Dox (Clontech). The cells were harvested 96 h
post transfection and were collected by centrifugation (10min
@ 14,000 RPM). Genomic DNA was extracted using a the
QIAamp DNA Mini Kit, (Qiagen, Cat #51304) following the
manufacturer’s instructions. A 466 base pair region containing
the Tet2 gRNA target site was PCR amplified from genomic
DNA in a standard 25 µl PCR reaction (Platinum Taq;
Invitrogen) using the following previously described DNA
primers (Tet2 Surv FP CAGATGCTTAGGCCAATCAAG and
Tet2 Surv RP AGAAGCAACACACATGAAGATG; Wang et al.,
2013). One hundred and fifty nanograms of isolated genomic
DNA (described above) was used as the DNA template, and the
PCRwas performed with the following cycling parameters [94◦C,
2min; (94◦C, 30 s; 54◦C, 30 s; 72◦C, 30 s) × 37 cycles, 72◦C, 45
s]. Amplification was confirmed using gel electrophoresis on a
1.5% agarose, 1 X TAE gel. Three microliters of PCR product
was digested with 5 units of EcoRV-HF (New England Biolabs)
for 2 h in a standard 10 µl restriction enzyme reaction following
the manufacturer’s instructions. Each 3 µL of digested PCR
product was electrophoresed on a 2.0% agarose, 0.5 X TBE gel
to determine if genome editing had occurred. In some cases, the
amount of genome editing was quantified using ImageJ (U.S.
National Institutes of Health, Bethesda, Maryland, USA, http://
imagej.nih.gov/ij/). This was accomplished by measuring the
optical density peaks using the gel analysis feature. The peaks
for the cut DNA and non-cut DNA were selected and the label
peaks feature was used to determine the percentage of cut and
non-cut DNA in each individual sample. Some in vitro samples
were screened using the resolvase based mutation detection
kit (Guide-it Mutation Detection Kit, Clontech, Cat #631443)
following the manufacturer’s instructions.
Immunocytochemisty (ICC)
Glass coverslips were placed in 24 well cell culture plates
and treated with poly-l-lysine (0.1 mg/mL; Sigma) overnight.
The following day, the poly-l-lysine was removed and the
coverslips were washed 3 × with phosphate buffered saline
pH 7.4 (PBS). N2A cells were seeded at 65% confluency on
these glass coverslips. Twenty-four hours later, the cells were
transfected with AAV viral plasmids designed to express Cas9
and rtTA/gRNA plasmids using Lipofetamine 2000 (Invitrogen),
following the manufacturer’s instructions. Six hours post
transfection, media was replaced with fresh media and in some
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cases the media contained 10 µg/mL of Dox. The ICC procedure
was carried out 24 h post addition of doxycycline as previously
described (Holehonnur et al., 2015) using an anti-Cas9 antibody
(1:200; Diagenode, C15200203) and TxRed secondary antibody
(1:000; Life Technologies). The ICCs were imaged at 200X
magnification using a fluorescencemicroscope (Olympus, BX51).
The on and off Dox pictures were taken at the same exposure
conditions. An additional high exposure image was taken of the
off Dox samples to reveal the low level Cas9 expression. For ICCs
following viral transduction of 293FT cells, 1.6 µl of AAV2/DJ-
PTight-Cas9 (6E12 GC/mL) and 1 µl of AAV2/DJ-gRNA/rtTA-
GFP (1E13 GC/mL) were diluted in 200 µl of culture media
containing 2% FBS and it was applied to cells for 2 h, with gentle
rocking every 30min. Following the 2-h incubation, 400 µl of
culture media containing 18% FBS was added to the wells. Dox
was added to the wells 6 h later and the ICC was carried out 24 h
after the addition of Dox.
Viral Production, Purification, and Titering
Procedures were carried out as previously described
(Holehonnur et al., 2014). AAV2 genome plasmids were
pseudotyped as either AAV2/DJ8 or AAV2/DJ as specified.
Viruses were produced using a triple-transfection, helper-free
method into 293FT cells (Invitrogen) using polyjet (Signagen
Laboratories) following the manufacturer’s instructions for
AAV production. A total of 5 × 15 cm cell culture plates were
transfected per virus. Viruses were purified on an iodixanol
step gradient and further concentrated and purified using
Amicon Ultra-15 centrifugal filter units (Millipore). Purified
AAV was titered using a quantitative-PCR based titering method
as previously described (Holehonnur et al., 2014). All Cas9
transgene containing viruses were titered utilizing custom
Cas9 primers/probe (Custom Taqman gene expression assays,
Invitrogen). All GFP transgene containing viruses were titered
with (GFP Primer/Probe (ID# Mr04329676_mr; Invitrogen).
The results were reported as the number of DNAse resistant viral
particles as genome copies per milliliter (GC/ml).
Viral Infusion
Viral infusions targeting the mouse BLA were performed
similarly as described (Holehonnur et al., 2014). Briefly,
mice were rendered unconscious with an intra-peritoneal
injection of ketamine (100 mg/kg) and xylazine (10 mg/kg)
prior to stereotaxic surgery. Thirty-one gauge custom infusion
cannulas (C315G, PlasticsOne) were very securely inserted into
polyethylene tubing (I.D. 0.0150 in. O.D. 0.043 in., wall thickness
0.0140 in; A-M systems, Inc.) that were 50 cm in length. These
tubes were first backfilled with 1 x phosphate buffered saline, pH
7.4 (PBS), followed by sesame oil, where only 1× PBSwas present
in the∼5 cm region closest to the infusers to avoid getting sesame
oil in the brain. Syringes (2 µL, 23-gauge (88,500); Hamilton
Company)) were used for the viral infusion. The viral cocktail
was drawn up into the infusion cannula. Infusers were bilaterally
lowered into the BLA of mice [AP+1.6,ML± 3.3,−DV± 4.97]
and infused (1 µL/side) at a rate of 0.07 µL/min for 15min using
an infusion pump (New Era Pump Systems Inc., NE-300) The
AAV2/DJ-PTight-Cas9 and AAV2/DJ-gRNATet2/Empty/rtTA-GFP
viruses were co-infused bilaterally into the BLA, each at a titer
of 6E12 GC/mL (1 µl/side). The AAV2/DJ8-PMecp2-Cas9 and
AAV2/DJ8-gRNAiTet2/Empty viruses were co-infused bilaterally
into the BLA, each at a titer of 2.5E12 GC/mL (1µl/side). In cases
whenmice were provided Dox, it was supplied through their food
(Dox 1 g/kg; Bio-Serv).
Assessment of In vivo Genome Editing
At the appropriate time point, mice were euthanized via CO2
euthanasia and the brain was rapidly removed and frozen with
powdered dry ice and then stored at −80◦C. Tissue was then
mounted and sliced using a cryostat (Thermo Scientific) to
take coronal sections that contained the amygdala. When GFP
reporter signal was present in the amygdala, 200 µm punches
were taken within the amygdala with a 1mm punch tool (Fine
Science Tools) until the GFP signal ceased within the amygdala.
Punched tissue was stored at−80◦C. Tissue was homogenized in
a 1.7mL centrifuge tube with pestle and extracted in the same
manner as the in vitro experiments.
Sequencing of Edited DNA
N2A cells that were transfected with pX330Tet2 were prepared
for DNA extraction and PCR amplification as described above.
PCR product was digested with EcoRV and electrophoresed and
the DNA band exhibiting editing was excised from the gel and
purified using a gel purification kit (Qiagen). Gel purified DNA
was cloned into the PCR4 Topo vector using a Topo cloning
kit (Invitrogen) and transformed into Top10 cells (Invitrogen).
Colonies were screened for the presence of the Tet2 sequence
via PCR and PCR product was sent for DNA sequencing
(Retrogen Inc.).
Subjects
Adult C57BL/6 mice were used in this study. All animals
were housed individually and maintained on a 12 h light/dark
cycle. Food and water were provided ad libitum throughout the
experiments. Animal use procedures were in accordance with
the National Institutes of Health Guide for the Care and Use
of Laboratory Animals and were approved by the University of
Texas at Dallas Animal Care and Use Committee.
Statistical Analysis
Quantified genome editing data was analyzed using a
non-parametric Kruskal–Wallis individual sample comparison
or multiple sample comparison, with a probability threshold of
0.05. A one-way ANOVA, followed by a Fisher’s PSD post-hoc
analysis was used to compare the different inducible promoters.
A two-tailed T-test assuming equal variances was used to
compare samples analyzed with the mutation detection kit.
RESULTS
Construction of a Doxycycline Regulated
SpCas9 Transgene within an AAV2 Viral
Vector
Viral vectors are necessary to introduce the genetic components
of the CRISPR/Cas9 system into specific mammalian cells in
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vivo. Adeno-associated virus (AAV) is the vector of choice to use
within mammalian systems due to its high tolerability in vivo
(Daya and Berns, 2008) and because it is possible to produce
high titer AAV relatively easily that is capable of transducing a
large number of cells. In our first set of experiments, we focused
on designing an inducible CRISPR/Cas9 system that was suitable
for AAV delivery, where the SpCas9 transgene expression could
be regulated. To accomplish this, it was necessary to fit the
entire Cas9 transgene within AAV’s strict genome packaging
limit which hovers somewhere between 4.7 and 5 kb. This
packaging limit also includes the two inverted terminal repeats
that are ∼150 bases each, therefore limiting AAV’s ability to
deliver transgenes that are no larger than ∼4.4–4.7 kb. Since
the coding region of SpCas9 is ∼4.2 kb, this leaves very little
room for the promoter and 3′ untranslated sequences (UTR).
Because of this, we opted to design an AAV vector that harbored
the Cas9 coding region under the control of a truncated 2nd
generation tetracycline response element (TRE) promoter, PTight
(Figure 1A). Of the three generations of TRE promoters (TRE2,
Tight, TRE3G), the Tight promoter is the shortest of the three
promoters. We also truncated the promoter at the 5′ end so that
it only included 3 Tet operators (TetO), creating a promoter that
was ∼175 bps. To regulate the PTight-Cas9 transgene and deliver
the gRNA expression cassette, another AAV was developed, that
harbored a gRNA transgene, utilizing a U6 promoter, and an
additional transgene, containing a CMV promoter driving rtTA
(Tet-On Advanced) transcription factor expression. This virus
was also designed to express green fluorescent protein (GFP)
from an internal ribosomal entry site (IRES), following the rtTA
open reading frame (ORF; Figure 1A). In cells that receive both
the PTight-Cas9 virus and the gRNA/rtTA virus in the presence
of Doxycycline (Dox), rtTA would become activated, allowing
it to bind to the PTight promoter and drive Cas9 expression,
inducing genome editing. When Dox is not present, the system
theoretically should not be able to express Cas9 and therefore
genome editing should not be possible. We produced both of
these viral vectors pseudotyped as DJ serotype and transduced
293FT cells grown in culture in the presence or absence of Dox.
Forty-eight hours post viral transduction, immunocytochemistry
(ICC) was performed for Cas9 protein expression. The cells
exhibited GFP fluorescence, indicating that they were efficiently
transduced by the gRNA/rtTA-GFP virus. The ICC revealed a
dramatic increase in Cas9 expression in the presence of Dox,
indicating that our viral vectors appropriately expressed their
intended transgenes and it appeared that Dox could regulate
Cas9 expression (replicates of samples produced similar results;
Figure 1B).
Next, we wanted to determine if these viral vectors could
edit the genome in an inducible manner. To do this we
chose to utilize a previously described and validated gRNA
targeting the mouse Tet2 genomic locus. Tet2 is a member
of the Ten-eleven translocation (Tet) gene family, and is
involved in the enzymatic conversion of 5-methylcytosine (5
mC) to 5-hydroxymethylcytosine (5 hmC) to promote DNA
demethylation. In particular, this gRNA is designed to target a
genomic sequence that contains an EcoRV restriction enzyme
site that is directly adjacent to the Protospacer Adjacent Motif
(PAM) sequence (Figure 1C). The PAM site is the DNA sequence
immediately following the DNA sequence targeted by the Cas9
nuclease. The location of the restriction enzyme site provides the
ability to screen cells for genome editing, because Cas9 mediated
genome editing utilizing this gRNA would likely destroy the
enzyme site, and therefore genome editing can be accessed via
restriction fragment length polymorphism (RFLP) analysis to
assess the presence or absence of this restriction enzyme site.
To demonstrate this and to validate that this Tet2 targeting
gRNA indeed was capable of efficiently editing its intended target
site, we transfected the mouse neuroblastoma cell line Neuro-
2A (N2A), with the Cas9/gRNA expression plasmid pX330,
that contained the Tet2 gRNA (pX330Tet2). Ninety-six hours
post transfection, the cells were harvested and genomic DNA
was isolated, and the Tet2 locus was PCR amplified utilizing
PCR primers that flank the intended Cas9 cut site (Figure 1D,
lane 1). The full length uncut Tet2 PCR product is 466 bps.
In cells that did not receive gRNAs targeting the Tet2 locus
(pX330Empty), genome editing did not occur, and the EcoRV
digestion of the Tet2 PCR product yielded 2 bands at ∼200 bps
as expected (Figure 1D, lane 2). However, in cells that were
transfected with the pX330Tet2 plasmid, genome editing did
occur, as demonstrated by the fact that the EcoRV digestion was
not capable of digesting the entire pool of PCR product. In this
case, the digestion of the PCR product yielded fully digested
DNA, creating 2 bands at ∼200 bps and one undigested band
at ∼440 bps, indicating genome editing had occurred. In this
case, the amount of editing was ∼33% as determined by the
ratio of the digested and undigested bands (Figure 1D, lane 3).
We cloned and sequenced some of these edited PCR products to
better characterize the nature of Cas9 mediated Indel formation.
In the 6 independent clones we sequenced, Cas9 had created
deletions spanning 1–15 nucleotides, therefore underscoring the
utility of the RFLP screening (Figure 1E).
A Doxycycline Regulated SpCas9, within
AAV, Exhibits Leaky Expression, and
Genome Editing in a Doxycycline
Independent Manner
To determine if our PTight-Cas9 and gRNA/rtTA-GFP viral
plasmids could edit the Tet2 locus in a Dox dependent
manner, we cotransfected the PTight-Cas9 plasmid with the
gRNATet2/rtTA-GFP plasmid containing the Tet2 gRNA into
N2A cells in the presence and absence of Dox. As a
control, we also cotransfected the PTight-Cas9 plasmid with the
gRNAEmpty/rtTA-GFP plasmid that did not contain a gRNA into
N2A cells in the presence or absence of Dox. Ninety-six hours
post transfection, the cells were harvested and the genomic DNA
was isolated and examined for genome editing at the Tet2 locus
via PCR/RFLP analysis as described above. Cells that received the
PTight-Cas9 and gRNAEmpty/rtTA-GFP plasmids, did not exhibit
editing of the Tet2 locus, as expected. Cells that received the
PTight-Cas9 and the gRNATet2/rtTA-GFP plasmids did exhibit
editing of the Tet2 locus; however, the editing occurred in the
presence and the absence of Dox (similar results obtained in 3
independent samples per group; Figure 2A). Notably, there was
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FIGURE 1 | (A) AAV vector maps depicting AAV-PTight-Cas9 and AAV-gRNA/rtTA. AAV-PTight-Cas9 consists of a Cas9 transgene under the control of a Dox
inducible Tight promoter. AAV-gRNA/rtTA consists of a gRNA expression cassette and a rtTA (Tet-On Advanced) transgene controlled by a CMV promoter. It also is
designed to express GFP via an IRES element following the rtTA reading frame. (B) ICC for Cas9 and GFP was performed on 293FT cells transduced by
AAV-PTight-Cas9 and AAV-gRNA/rtTA viruses in the presence or absence of Dox. Native GFP expression is visible in virtually all of the cells (i, iii). Cas9 expression is
robustly induced in the presence of Dox (ii), compared to the no Dox condition (iv). Representative images are shown. The experiment was repeated twice with similar
results. (C) Diagram depicting the approximate location of where the Tet2 gRNA targets the Tet2 locus. Underlined nucleotides indicate the sequence of the Tet2
gRNA. Location of the EcoRV site and PAM sequence are denoted. (D) An approximate 460 bps region of the Tet2 locus that includes the site targeted for editing via
the gRNATet2, was PCR amplified from N2A genomic DNA and electrophoresed on a standard agarose gel and stained with ethidium bromide (lane 1). N2A cells were
transfected with the pX330Empty, a plasmid designed to express spCas9 and no gRNA, and 96 h later, the genomic DNA was isolated and the Tet2 locus was PCR
amplified and subjected to EcoRV digestion. The PCR product was cut into two pieces of DNA as expected (lane 2). However, when N2A cells were transfected with
pX330Tet2 and similarly processed, the PCR product was incompletely digested resulting in a total of three bands on the gel - one uncut PCR product (∼460 bps) and
two smaller bands. In this case the genome editing was ∼33%. (E) Edited DNA depicted in (D, lane 3) was gel purified and TA cloned and 6 independent clones were
sequenced. These 6 clones contained deletions which destroyed the EcoRV site.
no difference between the induced (i.e., Dox) samples, compared
to the non-induced samples (i.e., no Dox), indicating that there
might be a low level of Cas9 expression that is sufficient for
genome editing in the non-induced samples. To determine if
these viruses would function in an inducible manner in vivo,
we infused these viruses into the basal and lateral amygdala
(BLA) of mice. Specifically, AAV2/DJ-PTight-Cas9 and AAV2/DJ-
gRNATet2/rtTA-GFP were co-infused bilaterally into the BLA,
each at a titer of 6E12 GC/mL (1 µl/side) (Figure 2B). For a
control, AAV2/DJ-PTight-Cas9 and AAV2/DJ-gRNAEmpty/rtTA-
GFP were infused in a similar manner. Half of the animals in
the Tet2 group and half of the animals in the Empty group were
placed on a diet of 1 g/kg of Dox. Ten days following surgery,
the animals were sacrificed, and their BLA were microdissected.
The genomic DNA was isolated from the microdissected BLA
tissue and subjected to PCR/RFLP analysis to assess genome
editing at the Tet2 locus (Figure 2C). Animals that received
the AAV2/DJ-PTight-Cas9 and AAV2/DJ-gRNAEmpty/rtTA-GFP
viruses, did not exhibit editing of the Tet2 locus, as expected.
Animals that received the AAV2/DJ-PTight-Cas9 and AAV2/DJ-
gRNATet2/rtTA-GFP viruses did exhibit editing at the Tet2 locus,
but similarly to the in vitro experiments, the editing was not Dox
dependent (similar results obtained in 3 independent samples per
group; Figure 2D). Since these viral plasmids cannot be tightly
regulated using Dox, these vectors would not be suitable for
inducible genome editing in vitro or in vivo.
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FIGURE 2 | (A) The AAV-PTight-Cas9 plasmid and the AAV-gRNATet2-rtTA plasmid were cotransfected into N2A cells in the presence or absence of Dox. As a
control, the AAV-PTight-Cas9 plasmid and the AAV-gRNAEmpty-rtTA plasmid were co-transfected too. Nighty six hours post transfection, the cells were harvested, the
genomic DNA was isolated and PCR and RFLP analysis was performed to assess if genome editing had occurred at the Tet2 locus. Genome editing was not observed
in cells that had received the gRNAEmpty plasmid either in the presence or absence of Dox as expected. Cells that were transfected with a plasmid containing the
gRNATet2 plasmid, did exhibit editing, however the editing occurred in samples that were in the presence or absence of Dox, indicating that genome editing occurred
independently of Dox. Similar results were observed in at least 3 independent samples per group. (B) Image of a Nissl stained coronal mouse brain section with the
BLA highlighted in red [adapted from (Franklin and Paxinos, 2007)] (i). Image depicting GFP expression within BLA neurons in a similar anatomical coronal slice as in (i),
taken 10 days following BLA infusion of both AAV-gRNATet2-rtTA-GFP and AAV-PTight-Cas9 viruses (ii). (C) Timeline from infusion of virus into the mouse amygdala to
assessment of genome editing via RFLP analysis. (D) RFLP analysis of genome editing from BLA tissue transduced with AAV-PTight-Cas9 and AAV-gRNAEmpty-rtTA
or AAV-PTight-Cas9 and AAV-gRNATet2-rtTA from mice that were fed a diet that included Dox or a diet that did not include Dox. No genome editing occurred in
samples that received gRNAEmpty as expected. Genome editing did occur in BLA samples that received gRNATet2 however, genome editing occurred independently
of Dox administration. Two independent samples per group are shown. Similar results were observed in at least 3 independent samples per group.
We speculated that the inability to regulate genome editing
with our PTight-Cas9 vector was due to low level Cas9 expression
that was not rtTA dependent. Therefore, we created a number
of other AAV vectors with modifications to attempt to reduce
expression of Cas9 (Figure 3A). We first modified the PTight-
Cas9 vector by removing the C-terminal NLS sequence at the end
of the Cas9 ORF and adding a PEST sequence (PTight-Cas9PEST).
The removal of the NLS should decrease the efficiency of
Cas9 nuclear import which could reduce Cas9 activity and the
addition of the PEST sequence could reduce the half-life of
the Cas9 protein, thus reducing Cas9 levels. We subsequently
modified PTight-Cas9PEST by exchanging the Tight promoter for
a truncated 3rd generation TRE3G promoter which contained 2
TetOs in hopes that the TRE3G promoter might lead to lower
background Cas9 expression (PTRE3G-Cas9PEST). Finally, we
modified the PTRE3G-Cas9PEST vector by removing the Kozak
sequence and the N-terminal NLS (PTRE3G-1Cas9PEST). The
removal of the Kozak sequence, might lead to less efficient
translation initiation, possibly lowering Cas9 protein levels,
and the removal of the N-Terminal NLS should reduce the
efficiency of Cas9 nuclear import, leading to reduced Cas9
activity. These 4 viral vectors were transfected into N2A cells
with the gRNATet2/rtTA-GFP and gRNAEmpty/rtTA-GFP vectors
in the presence or absence of Dox and genome editing of the Tet2
locus was assessed via PCR/RFLP analysis as described above
(Figure 3B). Genome editing of the Tet2 locus did not occur in
the gRNAEmpty groups as expected (Data not shown). Cells that
received the Cas9 viral plasmids and the gRNATet2/rtTA-GFP
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FIGURE 3 | (A) AAV vector maps depicting AAV-PTight-Cas9 and three new vectors derived from AAV-PTight-Cas9. The C-terminal NLS was removed from
AAV-PTight-Cas9 and replaced with a PEST sequence to create AAV-PTight-Cas9PEST. Then the Tight promoter was exchanged for a TRE3G promoter to create
PTRE3G-Cas9PEST. Next, the kozak sequence and N-term NLS was removed to create PTRE3G-1Cas9PEST. (B) The plasmids described in (A), were co-transfected
with AAV-gRNATet2-rtTA into N2A cells in the presence or absence of Dox. Nighty six hours post transfection, the cells were harvested, the genomic DNA was isolated
and PCR and RFLP analysis was performed to assess if genome editing had occurred at the Tet2 locus. None of the Cas9 plasmids exhibited genome editing that
was Dox dependent. Similar results were observed in at least 3 independent samples per group. (C) These Cas9 plasmids were transfected into N2A cells in the
presence or absence of Dox and an ICC for Cas9 was performed. Images depict cellular Cas9 expression from cells treated with Dox (i, v, ix, and xiii) or off Dox (ii, vi,
x, xiv, and xvii). These images were taken the same exposure. Images depicted in (iii, vii, xi, xv, and xviii) are of the off Dox samples at a higher exposure, which reveal
low amounts of Cas9 expression in the absence of Dox. Images depicted in (iv, viii, xii, and xvi) are a zoom-in of the on Dox samples that shows a decreased nuclear
localization of Cas9 protein for the PTRE3G-1Cas9PEST group. Samples were processed in duplicate with similar results. UTC, untransfected control.
plasmid did exhibit editing of the Tet2 locus, however, there
was virtually no differences in editing in the presence or the
absence of Dox (similar results obtained in 3 independent
samples per group). Next, we transfected N2A cells with the four
Cas9 viral plasmids and the gRNATet2/rtTA-GFP viral plasmid
in the presence or absence of Dox. Twenty-eight hours post
transfection, the cells were examined by immunocytochemistry
(ICC), to observe Cas9 expression (Figure 3C). In all cases there
was a clear induction of Cas9 expression due to the presence of
Dox. Using exposure conditions that were optimal for visualizing
Cas9 expression in the presence of Dox, there appeared to
be very little, if any, Cas9 expression in the absence of Dox.
However, at a much higher exposure time there was obvious
Cas9 expression in the absence of Dox, which explains the
genome editing we observed in the absence of Dox (samples
performed in duplicate with similar results). Interestingly, these
findings underscore that very little Cas9 protein is needed for
efficient genome editing. We did not observe obvious differences
in Cas9 expression across these four Cas9 viral constructs,
indicating that the presence of the PEST sequence, the use of
the TRE3G promoter and removal of the Kozak sequence had
little influence over Cas9 steady state protein levels in the on or
off Dox conditions. The removal of the N and C terminal Cas9
NLSs did have a noticeable influence on the steady state Cas9
cellular localization, which became predominantly localized to
the cytoplasm.
AAV gRNAi Vector Exhibits Doxycycline
Dependent Genome Editing In vitro and
In vivo
Since we were not able to generate an AAV based Cas9
expression system where Cas9 expression could be regulated
using a TRE containing promoter, due to the leakiness of Cas9
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FIGURE 4 | (A) AAV vector maps depicting the AAV-PMecp2-Cas9 vector and an inducible gRNA vector, AAV-gRNAi-TetR-GFP. (B) The gRNAi plasmid described in
(A), containing either a Tet gRNA or no gRNA (Empty), were co-transfected with pX330Empty into N2A cells in the presence or absence of Dox. Nighty six hours post
transfection, the cells were harvested, the genomic DNA was isolated and PCR, and RFLP analysis was performed to assess if genome editing had occurred at the
Tet2 locus. Genome editing was not observed in cells that had received the gRNAEmpty plasmid either in the presence or absence of Dox as expected. Cells that were
transfected with a plasmid containing the gRNATet2 plasmid, did exhibit editing in the presence of Dox, but not in the absence of Dox, indicating that genome editing
could be regulated in a Dox dependent manner. Similar results were observed in at least 3 independent samples per group. (C) The H1/TO promoter gRNA
expression cassette was compared to gRNA expression cassettes composed of either a full length H1/TO promoter (H1-L/TO), a U6/TO promoter or a non-inducible
U6 promoter (U6) for their ability to edit the Tet2 locus. Cells were transfected with the respective vectors in the presence or absence of Dox and genome editing was
assessed 96 h post transfection (n = 4 per groups). (D) Quantification of genome editing revealed that the inducible promoter gRNA expression cassettes were not
significantly different from each other (n.s. = p ≤ 0.0778) in their ability to edit the Tet2 locus and they were all slightly but significantly different from the non-inducible
U6 promoter construct (*p ≤ 0.003). Four independent samples were screened with similar results. (E) Partial sequences of the inducible promoters used, highlighting
the tetracycline operators (Tet-O) and transcriptional start site. (F) Genomic DNA from the same U6, H1/TO, and UTC samples used for (C,D) were subjected to a
mutation detection kit (Clontech), in which the PCR amplified product was denatured, annealed and digested with Resolvase to directly detect edited DNA. (G) Levels
of editing were comparable to those seen using the restriction digest PCR/RFLP analysis used for (C,D). Again, levels of editing were significantly higher in the U6
group, compared to the H1/TO group (#p ≤ 0.005, Two Tailed T-test).
expression within this system, we chose an alternative approach.
We reasoned that if we could regulate gRNA expression, we
could still generate an inducible viral mediated genome editing
system. We generated a gRNA AAV vector containing a gRNA
transgene controlled by a hybrid H1/TO promoter (gRNAi)
similar to the promoter used in the BLOCK-iT inducible H1
RNAi vectors (Invitrogen; Figure 4A). This vector also contains
a CMV promoter controlling the expression of TetR in frame
with a self-cleaving P2A sequence followed by a GFP ORF fused
to a KASH domain. Binding of TetR to the H1/TO promoter
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represses the gRNA transcription. The addition of Dox inhibits
TetR binding and induces gRNA expression. The KASH domain
will localize the GFP protein to the nuclear membrane, which
will allow the nuclei of transduced neurons within the brain to be
isolated away from non-transduced neurons using a combination
of nuclei isolation via cellular fractionation and fluorescence-
activated cell sorting (FACS). To test if the gRNA could regulate
genome editing in a Dox dependent manner, we co-transfected
the gRNAiTet2-TetR viral vector containing a gRNA designed
to edit the Tet2 locus with a Cas9 expression plasmid that
did not contain a gRNA (pX330Empty) into N2A cells, in the
presence or absence of Dox. As a control, we co-transfected the
gRNAiEmpty-TetR viral vector which did not contain a gRNA
with pX330Empty in the presence or absence of Dox. Ninety-six
hours post transfection, the genome editing of the Tet2 locus
was assessed via PCR/RFLP analysis as described above. Cells
that received the gRNAiEmpty-TetR vector did not exhibit genome
editing as anticipated. Cells that received the gRNAiTet2-TetR
viral vector in the presence of Dox, exhibited genome editing,
but in the absence of Dox, there was no editing (similar results
obtained in 3 independent samples per group; Figure 4B). These
data indicated that the gRNAi-TetR vector could provide a
plausible system for inducible viral mediated genome editing.
To test the efficiency of the H1/TO gRNA expression cassette,
we compared its ability to mediate genome editing in vitro
to two different inducible promoter based gRNA expression
cassettes and a standard U6 based gRNA expression cassette (U6;
pX552). We designed a gRNA expression cassette that included
the full length sequence for the H1 promoter (H1-L/TO) and a
U6/TO promoter based gRNA expression cassette, as described in
Henriksen et al. (2007) (Figure 4E). These different vectors, were
cotransfected with pX330Empty into N2A cells, in the presence
or absence of Dox for 96 h. PCR/RFLP analysis revealed that
the U6 group exhibited moderately better editing compared to
the U6/TO, H1/TO and H1-L/TO groups [F(3, 12) = 13.157, p =
0.0004] (p < 0.003; Figures 4C,D). We suspect that the presence
of the Tet Operators, may slightly interfere with the efficiency
of gRNA expression, however the inducible gRNA vectors do
exhibit significant Dox dependent genome editing.
In order to determine if our restriction enzyme screening
method to detect genome editing was comparable to other
commonmethods that are designed to detect genome editing, we
screened the same U6 and H1/TO samples from above utilizing
the Resolvase based mutation detection kit (Clontech). The PCR
products were denatured, annealed and digested with Resolvase,
an enzyme that makes a DSB at the site of mismatched DNA.
The screening revealed a significant difference between the U6
and H1/TO groups [t(6) = 4.332, p = 0.0049], as expected.
Additionally, similar levels of editing were detected utilizing
this mutation detection method compared to the PCR/RFLP
restriction enzyme analysis method (Figures 4F,G).
Next, we wanted to assess if the gRNAi virus could be
used in vivo to control genome editing in a Dox dependent
manner. In these experiments we used a previously developed
Cas9 AAV, where Cas9 expression is under the control of a
neuronal specific truncated Mecp2 promoter (AAVPMecp2-Cas9)
(Swiech et al., 2015). We produced AAV2/DJ8-PMecp2-Cas9
virus and the AAV2/DJ8-gRNAiTet2 virus pseudotyped as DJ8
serotype. Specifically, AAV2/DJ8-PMecp2-Cas9 and AAV2/DJ8-
gRNAiTet2 were co-infused bilaterally into the BLA, each at a titer
of∼2.5E12 GC/mL (1µl/side). For a control, AAV2/DJ8-PMecp2-
Cas9 and AAV2/DJ8-gRNAiEmpty were infused in a similar
manner. Half of the animals in the Tet2 group and half of the
animals in the Empty group were placed on a diet of 1 g/kg
of Dox. Ten and fourteen days following surgery, the animals
were sacrificed, and their BLA were microdissected. The genomic
DNA was isolated from the microdissected BLA tissue and
subjected to PCR/RFLP analysis to assess genome editing at the
Tet2 locus (Figure 5A). Animals that received the AAV2/DJ8-
PMecp2-Cas9 and AAV2/DJ8-gRNAiEmpty viruses did not exhibit
editing of the Tet2 locus as expected. Animals that received
the AAV2/DJ8-PMecp2-Cas9 and AAV2/DJ8-gRNAiTet2 viruses
did exhibit editing at the Tet2 locus, but this time editing only
occurred in cases where the animals received Dox, indicating
that genome editing could be regulated in a Dox dependent
manner (similar results obtained in 3 independent samples per
group; p= 0.04; Figures 5B,C). To compare our inducible system
to a non-inducible system, we co-infused mice with an AAV
designed to express a gRNA from a U6 promoter and AAV2/DJ8-
PMecp2-Cas9 at the same viral titers as the above experiments
and followed the same timeline as the above experiments. RFLP
analysis revealed similar levels of genome editing at day 10 and
14 for the conventional non-inducible genome editing system
(gRNA), compared to our inducible genome editing system
(gRNAi) in vivo (similar results obtained in 3 independent
samples per group; p < 0.28; Figures 5D,E). In these in vivo
experiments, we observed ∼20% genome editing. This in part
is due to the fact that our viral vectors are targeting neurons
selectively, due to AAV’s natural tropism for neurons in vivo (de
Solis et al., 2015) and the fact that Cas9 expression is controlled
from the Mecp2 promoter which restricts its expression to
neurons (Swiech et al., 2015). Within the brain, glia cells make
up at least 50% of the cells (Azevedo et al., 2009), so in this
case we would at best only expect 50% of the cells within the
microdissected brain tissue to exhibit editing and that is only if
all the neurons within this microdissected tissue were transduced
by both viruses. Therefore the ∼20% level of editing in vivo we
are obtaining essentially means we are observing ∼40% of the
neurons undergo genome editing, and this is similar between
our inducible system and the previously developed non-inducible
system.
In our last set of experiments, we wanted to determine the
duration animals would need to receive Dox to induce genome
editing. Therefore, in these experiments we infused AAV2/DJ8-
PMecp2-Cas9 andAAV2/DJ8-gRNAiTet2 virus into themouse BLA
as described above. In this case, we waited 10 days following
the infusion of the virus to administer Dox to the animals.
The animals were then taken off Dox 1, 5, or 7 days later.
The animals were sacrificed 5 days after Dox was removed
from their diet, and the transduced cells within the BLA were
microdissected. The genomic DNA was isolated from the tissue
and subjected to PCR/RFLP analysis to assess genome editing
at the Tet2 locus (Figure 6A). PCR/RFLP analysis (Figure 6B)
revealed that day 1, 5, and 7 time points demonstrated roughly
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FIGURE 5 | (A) Timeline from viral infusion to analysis of editing. Animals received either infusions of AAV-PMecp2-Cas9 and AAV-gRNAiTet2-TetR-GFP or
AAV-PMecp2-Cas9 and AAV-gRNAiEmpty-TetR-GFP and were put on Dox or control (no Dox) food for 10 or 14 days post-infusion. Animals were then sacrificed and
transduced cells within the amygdala were then microdissected and assessed for editing. (B) RFLP analysis of genome editing from BLA tissue transduced with
AAV-PMecp2-Cas9 and AAV-gRNAiTet2-TetR-GFP or AAV-PMecp2-Cas9 and AAV-gRNAiEmpty-TetR-GFP from mice that were fed a diet that included Dox or a diet
that did not include Dox and sacrificed 10 days post viral infusion. Genome editing did not occur in samples that received gRNAEmpty as expected. Genome editing
did occur in BLA samples that received gRNATet2 and this genome editing was dependent on Dox administration. Two independent samples per group are shown.
Similar results were observed in at least 3 independent samples per group. (C) RFLP Analysis at day 14 post-infusion showed comparable amounts of editing as
compared to the day 10 post-infusion experiments described in (B). One independent sample per group is shown. Similar results were observed in 3 independent
samples per group. (D) A comparison of our inducible gRNAi virus was compared to a non-inducible system (gRNA) in vivo, following the same timeline for day 10 and
14 as described in (B,C). (E) Quantification of total edited DNA in RFLP experiments revealed a similar degree of editing between the inducible and non-inducible
systems. Editing at both day 10 and 14 on Dox was significantly higher when compared to the no Dox group (*p = 0.04, Kruskal–Wallis). Editing after 10 days on Dox
with the gRNAi vector compared to the non-inducible vector (gRNA) was not significantly different between the two groups (ns = p = 0.51, Kruskal–Wallis). The same
was found for the 14 day time point (ns = p = 0.28, Kruskal–Wallis).
similar levels of editing (3 independent samples per group)
(Figure 6C). These data indicate that this system requires as
little as 1 day on Dox to induce editing. The degree of genome
editing within this experiment was roughly comparable to the
degree of genome editing obtained with the inducible and non-
inducible gRNA viruses utilized in the experiments described in
Figure 5E.
DISCUSSION
Here, we report the creation of an inducible CRISPR/Cas9 system
that can be delivered to cells in vitro and in vivo via AAV. Genome
editing in this system is regulated by a doxycycline inducible
gRNA. We examined editing in vivo within the mouse brain at
10 and 14 days post viral infusion and observed a similar level
of editing between both time points and the amount of editing
was very similar and comparable to a non-inducible system. We
also determined that this system is highly dependent on Dox
to initiate genome editing in vitro and in vivo and therefore
there does not appear to be any genome editing when Dox is
not present. Administering animals Dox containing food for as
little as 1 day (following 10 days post viral infusion) yielded
roughly similar levels of genome editing to all other time points
tested. We believe this system could be extremely useful for in
vivo studies where regulating CRISPR/Cas9 genome editing in a
temporally and spatially restricted manner would be beneficial.
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FIGURE 6 | (A) Timeline from viral infusion to RFLP analysis of genome editing. Animals were infused into the BLA with AAV-Pmecp2-Cas9 and
AAV-gRNAiTet2-TetR-GFP. Ten days post-infusion animals were placed on Dox food and then Dox food was removed either 1, 3, or 5 days later. Animals were
sacrificed 5 days after removal of Dox and the BLA was microdissected and the genomic DNA was isolated and subjected to RFLP/ PCR analysis. (B) RFLP analysis of
editing across 1, 5, and 7 days on Dox showed similar levels of editing and no editing in a gRNAiEmpty no Dox control. (C) Quantification of total edited DNA revealed
similar editing across days animals were on Dox. These levels of genome editing were very similar to the levels seen during the 10 and 14 day editing time course for
the gRNAi system and the non-inducible system. Percent genome editing was not significantly different between 1, 5, and 7 days on Dox (p = 0.67, Kruskal–Wallis).
Certainly, behavioral neuroscience could benefit from this system
because it would allow a gene to be knocked out at a specific time
point during an ongoing behavioral assay that may span days
to weeks.
Initially, we attempted to regulate the expression of Cas9 using
a tetracycline response element (TRE) containing promoter;
however, we determined that genome editing could not be
regulated in a Dox dependent manner, due to the leakiness
of Cas9 expression within this system. Some studies have
described regulating Cas9 expression utilizing TRE containing
promoters in other systems fairly successfully with limited
leakiness (González et al., 2014; Dow et al., 2015). In these cases,
the TRE—Cas9 transgene was stably integrated into the genome,
which might reduce the observed leakiness because the transgene
copy number may be lower. In comparison, ectopic expression
methods such as plasmid transfection and viral transduction, can
deliver hundreds to thousands of copies of plasmid or virus,
and this may lead to an increase in leakiness, as seen in our
experiments since the transgene copy number is so high. It is
also possible that the low level Cas9 expression we observed in
the non-induced state is driven in part by low level promoter
activity from the inverted terminal repeat (ITR), since it’s well
established that the AAV ITRs can serve as weak promoters for
RNA polymerase II (Wang et al., 1999).
Several inducible systems have been developed for
CRISPR/Cas9 based systems where either the expression of
Cas9 or the gRNA are inducible; however, none of these systems,
to date, have been adapted for AAV delivery. Kiani et al.
demonstrated that gRNA expression could be regulated from
a polymerase II, TRE3G promoter in CRISPRi experiments
conducted in HEK293 cells (Kiani et al., 2014). More systems
have been developed where Cas9 expression or activity is
regulated. One such system is light inducible, in which Cas9
is present in cells in an inactive or incomplete form, and
with the addition of light, Cas9 becomes active and is able
to complex with the gRNA and edit the target gene in vitro
(Nihongaki et al., 2015). Qi and colleagues developed an
anhydrotetracycline (aTc)-inducible Cas9 expression system
for use in bacterial CRISPRi experiments (Qi et al., 2013).
Davis and colleagues developed a system where inactive Cas9
becomes active in the presence of tamoxifen to enable genome
editing (Davis et al., 2015) and Zetsche and colleagues developed
an inducible system where Cas9 becomes active upon the
addition of rapamycin (Zetsche et al., 2015). The tamoxifen
inducible system in its current form would not be amenable
to AAV delivery, due to AAV’s genome packaging limits
and the rapamycin inducible system would not be an ideal
system to use in vivo, given rapamycin inhibits the mammalian
target of rapamycin (mTOR), which is essential for many
cellular processes (Ballou and Lin, 2008; Laplante and Sabatini,
2009) including those for memory formation (Nader et al.,
2000).
To our knowledge, this is the first example of an
inducible AAV mediated CRISPR/Cas9 system where the
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expression of the gRNA is regulated in vivo. One of the
great features of this system is that the inducible gRNA
vector (gRNAi) we developed might be cross compatible
with many existing S. pyogenes Cas9 (SpCas9) systems.
Coupling our gRNAi AAV vector with these systems may
enable them to be inducible as well (i.e., Cas9 mouse,
CRISPRi, etc.).
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